CVS Health
🇺🇸 NYSE:CVS
•
Dec 31, 2024
CVS Health Q4 2024 Earnings Report
Key Takeaways
CVS Health reported Q4 2024 revenue of $97.71 billion, up 4.2% YoY, but experienced a decline in operating income and net income due to pressures in the Health Care Benefits segment. GAAP EPS fell to $1.30 from $1.58, and Adjusted EPS dropped to $1.19 from $2.12.
CVS Health Revenue
CVS Health EPS
CVS Health Revenue by Segment
Forward Guidance
CVS Health provided a 2025 Adjusted EPS guidance range of $5.75 to $6.00, with GAAP EPS expected between $4.58 and $4.83. Cash flow from operations is projected to be approximately $6.5 billion.
Positive Outlook
- Continued revenue growth across key segments, particularly in Pharmacy & Consumer Wellness.
- Expected improvements in Medicare Advantage star ratings in future years.
- Focus on cost optimization and operational efficiency improvements.
- Growth in specialty pharmacy and increased utilization in health services.
- Expanding digital and in-home health care offerings.
Challenges Ahead
- Ongoing pressures in the Health Care Benefits segment due to higher utilization rates.
- Impact of lower Medicare Advantage star ratings affecting reimbursement rates.
- Declining operating income despite revenue growth.
- Increased competition in pharmacy and health services markets.
- Potential macroeconomic headwinds affecting consumer spending.
Revenue & Expenses
Visualization of income flow from segment revenue to net income